European Graft Versus Host Disease (GVHD) Market Insights, Epidemiology and Market Forecasts 2016-2023 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Graft versus Host Disease (GVHD) - Market Insights, Epidemiology and Market Forecast - 2023 - EU5" drug pipelines to their offering.

European Graft versus Host Disease (GVHD) - Market Insights, Epidemiology and Market Forecast 2023 report provides an overview of the disease and global historical and forecasted epidemiological data for the diagnosed incident cases of Hematopoietic stem cell transplantations (HSCTs) and Graft Versus Host Disease (GVHD) based upon the sub-types of GVHD along with the type of donor involved in the HSCTs, for the forecast period (2013-2023).

GVHD is one of the severe complications associated with Hematopoietic stem cell transplantations (HSCTs). Our forecasts predict an on-going increase in HSCTs in the near future which shall lead to subsequent increase in the patient population of GVHD. According to estimates, the total number of diagnosed incident cases of Hematopoietic Stem Cell Transplants (HSCTs) shall increase at a Compound Annual Growth Rate (CAGR) of 2.71% from 2013-2023 and reach up to 30,328 cases in the year 2023.

The incident rate of GVHD in unrelated donor (URD) is much higher in comparison to the sibling donors (SD), irrespective of the sub-types i.e., acute GVHD (aGVHD) or chronic GVHD (cGVHD). As per our forecasts, the diagnosed incidence cases of aGVHD in sibling donors and aGVHD in unrelated donors, shall increase at a CAGR of 3.96% and 4.05%, respectively, from 2013-2023. In case of GVHD, the number of diagnosed incident population cGVHD in sibling donors and cGVHD in unrelated donors is expected to accentuate at a CAGR of 4.05% and 4.04%, respectively, by the end of the year 2023.

Key Topics Covered:

  1. Graft Versus Host Disease (GVHD)
  2. Disease Definition
  3. Disease Types
  4. Acute GvHD
  5. Chronic GvHD
  6. Grades of GvHD
  7. Pathophysiology
  8. Risk Factors for GVHD
  9. Diagnosis
  10. Epidemiology and Patient Population
  11. Key Points
  12. Germany
  13. France
  14. Spain
  15. Italy
  16. United Kingdom
  17. Assumptions and Rationale
  18. Appendix

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/p6xl7n/graft_versus_host

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Immune Disorders Drugs, Immunosuppressive Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Immune Disorders Drugs, Immunosuppressive Drugs